# A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Source: https://onco.cc/trials/nct06136650/  
OnCo record `nct06136650` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Opevesostat in prostate cancer, now recruiting.

## Summary

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) is a phase 3 interventional study registered as NCT06136650, led by Merck Sharp & Dohme, and recruiting on the registry. Official title: MK-5684-004: A Phase 3, Randomised, Open-label Study of Opevesostat Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA) (OMAHA-004). Planned enrolment is 1314 participants (estimated). The study started in 2023-12-18 and primary completion is expected in 2028-05-10. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: OMAHA-004
- Tags: ctgov-ingest
- Registry id: NCT06136650
- Phase: 3
- Setting: MK-5684-004: A Phase 3, Randomized, Open-label Study of Opevesostat Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA) (OMAHA-004)
- Sponsor: Merck Sharp & Dohme
- Enrolled: 1314

## Sources

- ClinicalTrials.gov NCT06136650: https://clinicaltrials.gov/study/NCT06136650

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Opevesostat](https://onco.cc/drugs/opevesostat/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct06136650.json